Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9344
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Eol Jeong, Han | - |
dc.contributor.author | Choi, Junyeong | - |
dc.contributor.author | Oh, In-Sun | - |
dc.contributor.author | Son, Hyunjin | - |
dc.contributor.author | Hun Jang, Seung | - |
dc.contributor.author | Young Jung, Sun- | - |
dc.contributor.author | Shin, Ju-Young | - |
dc.date.accessioned | 2024-12-19T04:58:59Z | - |
dc.date.available | 2024-12-19T04:58:59Z | - |
dc.date.issued | 2022-10-01 | - |
dc.identifier.issn | 1684-1182 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9344 | - |
dc.description.abstract | Abstract Background/Purpose(s): The World Health Organization (WHO) released treatment guidelines for multidrug resistant tuberculosis (MDR-TB) in 2008, with subsequent revisions in 2011; Korea disseminated corresponding guidelines in 2011 and 2014, respectively. Thus, we aimed to investigate the temporal trends of and the updated guideline’s impact on the prescription patterns of anti-TB drugs. Methods: We conducted a time-series study using Korea’s nationwide healthcare database (2007e2015), where patients with TB or MDR-TB were included. Only anti-TB drugs prescribed during the intensive phase of treatment for TB (two months) or MDR-TB (eight months) were assessed. We estimated the annual utilization of TB treatment regimens and the relative difference (RD) in the proportion of MDR-TB treatment medications between the following periods: before the first Korean guideline (June 2008 to March 2011); between the first andrevised guidelines (April 2011 to July 2014); after the revised guideline (August 2014 to December 2015). Results: Of 3523 TB (mean age 54.1 years; male 56.8%) patients, treatment regimens for TB complied with guideline recommendations as >80% of patients received either quadruple (mean 66.8%) or triple (14.5%) therapy of first-line anti-TB drugs. Following the WHO’s guideline update, prescription patterns changed accordingly among 111 MDR-TB (mean age 46.0 years; male 67.6%) patients, as use of pyrazinamide (RD þ20.3%) and prothionamide (þ11.5%) increased (recommended to be compulsory), and streptomycin (43.1%) decreased (ototoxicity risks). Conclusions: Anti-TB drug prescription patterns for both TB and MDR-TB well reflected WHO’s treatment guideline as well as corresponding domestic guidelines of South Korea | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Taiwan LLC | en_US |
dc.subject | Multidrug resistant tuberculosis; | en_US |
dc.subject | Nationwide study; | en_US |
dc.subject | Prescription patterns; | en_US |
dc.subject | Time series; | en_US |
dc.subject | Tuberculosis | en_US |
dc.title | Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 55 NO 5 2022 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
917-925.pdf | 1.07 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.